SCHEMBL14880002

SCHEMBL14880002

COC(=O)c1cccc(NC(=O)C=C(C)C)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.77
▸ KMT2A Q03164 4/20 0.77
▸ RAB9A P51151 5/20 0.61
▸ ALDH1A1 P00352 3/20 0.60
▸ NPC1 O15118 3/20 0.58
▸ HIF1A Q16665 1/20 0.57
▸ MAPT P10636 5/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ TP53 P04637 2/20 0.56
▸ CYP1A2 P05177 2/20 0.55
▸ CYP3A4 P08684 2/20 0.55
▸ CYP2C19 P33261 2/20 0.55
▸ CYP2D6 P10635 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ PARP1 P09874 1/20 0.55
▸ PARP15 Q460N3 1/20 0.55
▸ PARP10 Q53GL7 1/20 0.55
▸ MAPK1 P28482 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ HTT P42858 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30183858 1.00 MEN1 (0.77) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL11754128 0.87 KMT2A (1.00) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL14879671 0.84 MEN1 (0.82) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL863169 0.82 RAB9A (0.71) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL6574403 0.80 KMT2A (0.65) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL11677217 0.80 MEN1 (0.74) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL11677222 0.80 MEN1 (0.74) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL12835093 0.80 ALDH1A1 (0.79) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL9312293 0.79 MEN1 (0.73) MEN1KMT2ARAB9AALDH1A1NPC1
SCHEMBL11654124 0.79 RAB9A (0.71) MEN1KMT2ARAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081521-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2025-12-10 — — EP disclosed
CN-115605476-B Substituted tricyclic compounds 鲁宾有限公司 2024-05-24 — — CN disclosed
US-11970448-B2 Monomers capable of dimerizing in an aqueous solution, and methods of using same CORNELL UNIVERSITY (US) 2024-04-30 — — US disclosed
US-20230119316-A1 Substituted Tricyclic Compounds LUPIN LIMITED (IN) 2023-04-20 — — US disclosed
CN-115605476-A Substituted tricyclic compounds 鲁宾有限公司(IN) 2023-01-13 — — CN disclosed
EP-4081521-A1 SUBSTITUTED TRICYCLIC COMPOUNDS Lupin Limited (IN) 2022-11-02 — — EP disclosed
WO-2021130731-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-07-01 — — WO disclosed
WO-2021130731-A1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LIMITED (IN) 2021-07-01 — — WO disclosed
US-20200354319-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME UNIV CORNELL (US) 2020-11-12 — — US disclosed
US-20200354319-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME UNIV CORNELL (US) 2020-11-12 — — US disclosed
US-20140194383-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CORNELL UNIVERSITY (US) 2014-07-10 — — US disclosed
US-20140194383-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CORNELL UNIVERSITY (US) 2014-07-10 — — US disclosed
EP-2694707-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME Cornell University (US) 2014-02-12 — — EP disclosed
WO-2013058824-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CORNELL UNIVERSITY (US) 2013-04-25 — — WO disclosed
WO-2013058824-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CORNELL UNIVERSITY (US) 2013-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11970448-B2 Monomers capable of dimerizing in an aqueous solution, and methods of using same CALCOCO2, MDN1, MBNL1 MEN1 199/4885KMT2A 4317/4885RAB9A 4060/4885
US-20230119316-A1 Substituted Tricyclic Compounds SOS1, RSU1, KSR1 MEN1 44/4885KMT2A 4266/4885RAB9A 154/4885
US-20200354319-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CALCOCO2, MDN1, MBNL1 MEN1 199/4885KMT2A 4317/4885RAB9A 4060/4885
US-20140194383-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CALCOCO2, MDN1, MBNL1 MEN1 199/4885KMT2A 4317/4885RAB9A 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback